Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
New Approaches to Neuroblastoma Therapy Consortium
With
OBJECTIVES: Primary * To determine the maximum tolerated dose of vorinostat in combination with iobenguane I 131 in patients with resistant or relapsed neuroblastoma. * To define the toxicities of vorinostat in combination with therapeutic doses of iobenguane I 131 in these patients. Secondary * To describe, within the context of a phase I study, the response rate in patients treated with vorinostat and iobenguane I 131. * To describe histone acetylation levels and norepinephrine transporter mRNA levels in peripheral blood mononuclear cells after treatment with different doses of vorinostat. OUTLINE: This is a multicenter study. Patients receive oral vorinostat once daily on days 1-14 and iobenguane I 131 IV over 1½-2 hours on day 3. Patients undergo autologous peripheral blood stem cell transplantation on day 17. Blood samples may be collected periodically for correlative biological studies. After completion of study treatment, patients are followed up periodically.
Age
2–30
Sex
ALL
Healthy volunteers
Not accepted